Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | ERN1 | O75460 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640070 | 1.00 | CASP1 (0.61) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6448836 | 1.00 | CASP1 (0.61) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6822831 | 1.00 | CASP1 (0.61) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4258545 | 0.82 | CASP1 (0.59) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4346774 | 0.80 | CASP1 (0.62) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4346769 | 0.80 | CASP1 (0.62) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| Ammonia Solution, Strong SCHEMBL10609635 | 0.79 | CASP1 (0.60) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL30495458 | 0.79 | KMT2A (0.69) | CASP1ERN1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL9316913 | 0.78 | MAPT (0.58) | SMN1; SMN2KMT2AKDM4EGAAMAPT | |
| SCHEMBL11343000 | 0.78 | ERN1 (0.68) | CASP1ERN1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| CN-111712489-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11565995-B2 | Methods of forming imines, imine-related and imine-derived compounds using green solvents | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210323911-A1 | METHODS OF FORMING IMINES, IMINE-RELATED AND IMINE-DERIVED COMPOUNDS USING GREEN SOLVENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-21 | — | — | US | disclosed |
| EP-3724173-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-09-22 | — | — | EP | disclosed |
| EP-3724173-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-09-22 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-111712489-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-09-25 | — | — | CN | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| WO-2019115781-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CASP1 1691/4885ERN1 1159/4885SMN1; SMN2 1269/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CASP1 2163/4885ERN1 2334/4885SMN1; SMN2 13/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CASP1 1486/4885ERN1 1272/4885SMN1; SMN2 4633/4885 |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CASP1 2163/4885ERN1 2334/4885SMN1; SMN2 13/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CASP1 2163/4885ERN1 2334/4885SMN1; SMN2 13/4885 |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CLCN2, SCN1B, CACNB1 | CASP1 2018/4885ERN1 2933/4885SMN1; SMN2 11/4885 |
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CLIC1, RYR2 | CASP1 1883/4885ERN1 2946/4885SMN1; SMN2 44/4885 |
| US-20210323911-A1 | METHODS OF FORMING IMINES, IMINE-RELATED AND IMINE-DERIVED COMPOUNDS USING GREEN SOLVENTS | IK, LDHB, IDH3B | CASP1 2555/4885ERN1 249/4885SMN1; SMN2 472/4885 |
| US-11565995-B2 | Methods of forming imines, imine-related and imine-derived compounds using green solvents | IK, LDHB, IDH3B | CASP1 2555/4885ERN1 249/4885SMN1; SMN2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.